



## **Armetheon to Present at the 22<sup>nd</sup> Annual Newsmakers in the Biotech Industry Conference**

**Milpitas, CA, September 8, 2015** – Armetheon, Inc., a specialty pharmaceutical company developing novel small molecule drugs for cardiovascular diseases, today announced that Dr. Sanjay Kakkar, Chief Executive Officer, will present a company overview at the 22<sup>nd</sup> Annual Newsmakers in the Biotech Industry Conference at the Millennium Broadway Hotel on Thursday, September 10, 2015 at 9:30a.m. Eastern Time in New York, NY.

### **About Armetheon**

Armetheon, Inc., is a privately held, specialty pharmaceutical company developing and commercializing innovative medicines addressing major unmet needs in cardiovascular disease, initially in thrombosis. Armetheon focuses on improved therapies with the goal of increased efficacy, safety, and utility, targeting specialty markets with clearly defined regulatory pathways. Armetheon's lead candidate, tecarfarin, is being investigated for use as a Vitamin K Antagonist and is currently in Phase 3 development for the prevention and management of thrombosis. For more information: [www.armetheon.com](http://www.armetheon.com).

### **Contacts**

For Armetheon:

Heather Lake, Director of Corporate Development

+1 650-646-3898, ext. 121

[hlake@armetheon.com](mailto:hlake@armetheon.com)

For Media: Justin Jackson

For Investor Inquiries: Ami Bavishi

Burns McClellan

+1 212-213-0006

[jjackson@burnsmc.com](mailto:jjackson@burnsmc.com)

[abavishi@burnsmc.com](mailto:abavishi@burnsmc.com)